The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pneumococcal Vaccine Polyvalent-Global Market Insights and Sales Trends 2025
Synopsis
Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.
The global Pneumococcal Vaccine Polyvalent market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pneumococcal Vaccine Polyvalent in various end use industries. The expanding demands from the 18 Years and Younger, 19 To 64 Years Old and 65 Years and Older,, are propelling Pneumococcal Vaccine Polyvalent market. Prevnar 13, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pneumovax23 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pneumococcal Vaccine Polyvalent, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pneumococcal Vaccine Polyvalent market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pneumococcal Vaccine Polyvalent market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pneumococcal Vaccine Polyvalent sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pneumococcal Vaccine Polyvalent covered in this report include Merck & Co. and Pfizer etc.
The global Pneumococcal Vaccine Polyvalent market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck & Co.
Pfizer
Global Pneumococcal Vaccine Polyvalent market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pneumococcal Vaccine Polyvalent market, Segment by Type:
Prevnar 13
Pneumovax23
Global Pneumococcal Vaccine Polyvalent market, by Application
18 Years and Younger
19 To 64 Years Old
65 Years and Older
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pneumococcal Vaccine Polyvalent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.
The global Pneumococcal Vaccine Polyvalent market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pneumococcal Vaccine Polyvalent in various end use industries. The expanding demands from the 18 Years and Younger, 19 To 64 Years Old and 65 Years and Older,, are propelling Pneumococcal Vaccine Polyvalent market. Prevnar 13, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pneumovax23 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pneumococcal Vaccine Polyvalent, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pneumococcal Vaccine Polyvalent market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pneumococcal Vaccine Polyvalent market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pneumococcal Vaccine Polyvalent sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pneumococcal Vaccine Polyvalent covered in this report include Merck & Co. and Pfizer etc.
The global Pneumococcal Vaccine Polyvalent market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck & Co.
Pfizer
Global Pneumococcal Vaccine Polyvalent market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pneumococcal Vaccine Polyvalent market, Segment by Type:
Prevnar 13
Pneumovax23
Global Pneumococcal Vaccine Polyvalent market, by Application
18 Years and Younger
19 To 64 Years Old
65 Years and Older
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Pneumococcal Vaccine Polyvalent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Pneumococcal Vaccine Polyvalent Market Overview
1.1 Pneumococcal Vaccine Polyvalent Product Overview
1.2 Pneumococcal Vaccine Polyvalent Market Segment by Type
1.2.1 Prevnar 13
1.2.2 Pneumovax23
1.3 Global Pneumococcal Vaccine Polyvalent Market Size by Type
1.3.1 Global Pneumococcal Vaccine Polyvalent Market Size Overview by Type (2018-2029)
1.3.2 Global Pneumococcal Vaccine Polyvalent Historic Market Size Review by Type (2018-2023)
1.3.3 Global Pneumococcal Vaccine Polyvalent Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pneumococcal Vaccine Polyvalent Sales Breakdown by Type (2018-2023)
1.4.2 Europe Pneumococcal Vaccine Polyvalent Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Pneumococcal Vaccine Polyvalent Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales Breakdown by Type (2018-2023)
2 Global Pneumococcal Vaccine Polyvalent Market Competition by Company
2.1 Global Top Players by Pneumococcal Vaccine Polyvalent Sales (2018-2023)
2.2 Global Top Players by Pneumococcal Vaccine Polyvalent Revenue (2018-2023)
2.3 Global Top Players by Pneumococcal Vaccine Polyvalent Price (2018-2023)
2.4 Global Top Manufacturers Pneumococcal Vaccine Polyvalent Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pneumococcal Vaccine Polyvalent Market Competitive Situation and Trends
2.5.1 Pneumococcal Vaccine Polyvalent Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Pneumococcal Vaccine Polyvalent Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pneumococcal Vaccine Polyvalent as of 2022)
2.7 Date of Key Manufacturers Enter into Pneumococcal Vaccine Polyvalent Market
2.8 Key Manufacturers Pneumococcal Vaccine Polyvalent Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pneumococcal Vaccine Polyvalent Status and Outlook by Region
3.1 Global Pneumococcal Vaccine Polyvalent Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Pneumococcal Vaccine Polyvalent Historic Market Size by Region
3.2.1 Global Pneumococcal Vaccine Polyvalent Sales in Volume by Region (2018-2023)
3.2.2 Global Pneumococcal Vaccine Polyvalent Sales in Value by Region (2018-2023)
3.2.3 Global Pneumococcal Vaccine Polyvalent Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Pneumococcal Vaccine Polyvalent Forecasted Market Size by Region
3.3.1 Global Pneumococcal Vaccine Polyvalent Sales in Volume by Region (2024-2029)
3.3.2 Global Pneumococcal Vaccine Polyvalent Sales in Value by Region (2024-2029)
3.3.3 Global Pneumococcal Vaccine Polyvalent Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Pneumococcal Vaccine Polyvalent by Application
4.1 Pneumococcal Vaccine Polyvalent Market Segment by Application
4.1.1 18 Years and Younger
4.1.2 19 To 64 Years Old
4.1.3 65 Years and Older
4.2 Global Pneumococcal Vaccine Polyvalent Market Size by Application
4.2.1 Global Pneumococcal Vaccine Polyvalent Market Size Overview by Application (2018-2029)
4.2.2 Global Pneumococcal Vaccine Polyvalent Historic Market Size Review by Application (2018-2023)
4.2.3 Global Pneumococcal Vaccine Polyvalent Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pneumococcal Vaccine Polyvalent Sales Breakdown by Application (2018-2023)
4.3.2 Europe Pneumococcal Vaccine Polyvalent Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Pneumococcal Vaccine Polyvalent Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales Breakdown by Application (2018-2023)
5 North America Pneumococcal Vaccine Polyvalent by Country
5.1 North America Pneumococcal Vaccine Polyvalent Historic Market Size by Country
5.1.1 North America Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2018-2023)
5.1.3 North America Pneumococcal Vaccine Polyvalent Sales in Value by Country (2018-2023)
5.2 North America Pneumococcal Vaccine Polyvalent Forecasted Market Size by Country
5.2.1 North America Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2024-2029)
5.2.2 North America Pneumococcal Vaccine Polyvalent Sales in Value by Country (2024-2029)
6 Europe Pneumococcal Vaccine Polyvalent by Country
6.1 Europe Pneumococcal Vaccine Polyvalent Historic Market Size by Country
6.1.1 Europe Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2018-2023)
6.1.3 Europe Pneumococcal Vaccine Polyvalent Sales in Value by Country (2018-2023)
6.2 Europe Pneumococcal Vaccine Polyvalent Forecasted Market Size by Country
6.2.1 Europe Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2024-2029)
6.2.2 Europe Pneumococcal Vaccine Polyvalent Sales in Value by Country (2024-2029)
7 Asia-Pacific Pneumococcal Vaccine Polyvalent by Region
7.1 Asia-Pacific Pneumococcal Vaccine Polyvalent Historic Market Size by Region
7.1.1 Asia-Pacific Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Pneumococcal Vaccine Polyvalent Forecasted Market Size by Region
7.2.1 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Pneumococcal Vaccine Polyvalent Sales in Value by Region (2024-2029)
8 Latin America Pneumococcal Vaccine Polyvalent by Country
8.1 Latin America Pneumococcal Vaccine Polyvalent Historic Market Size by Country
8.1.1 Latin America Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2018-2023)
8.1.3 Latin America Pneumococcal Vaccine Polyvalent Sales in Value by Country (2018-2023)
8.2 Latin America Pneumococcal Vaccine Polyvalent Forecasted Market Size by Country
8.2.1 Latin America Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2024-2029)
8.2.2 Latin America Pneumococcal Vaccine Polyvalent Sales in Value by Country (2024-2029)
9 Middle East and Africa Pneumococcal Vaccine Polyvalent by Country
9.1 Middle East and Africa Pneumococcal Vaccine Polyvalent Historic Market Size by Country
9.1.1 Middle East and Africa Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Pneumococcal Vaccine Polyvalent Forecasted Market Size by Country
9.2.1 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Pneumococcal Vaccine Polyvalent Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Merck & Co.
10.1.1 Merck & Co. Company Information
10.1.2 Merck & Co. Introduction and Business Overview
10.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Products Offered
10.1.5 Merck & Co. Recent Development
10.2 Pfizer
10.2.1 Pfizer Company Information
10.2.2 Pfizer Introduction and Business Overview
10.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Pfizer Pneumococcal Vaccine Polyvalent Products Offered
10.2.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pneumococcal Vaccine Polyvalent Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pneumococcal Vaccine Polyvalent Industrial Chain Analysis
11.4 Pneumococcal Vaccine Polyvalent Market Dynamics
11.4.1 Pneumococcal Vaccine Polyvalent Industry Trends
11.4.2 Pneumococcal Vaccine Polyvalent Market Drivers
11.4.3 Pneumococcal Vaccine Polyvalent Market Challenges
11.4.4 Pneumococcal Vaccine Polyvalent Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pneumococcal Vaccine Polyvalent Distributors
12.3 Pneumococcal Vaccine Polyvalent Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
